Podcasts about mrna

In this eye-opening episode, we dive deep into the latest reports on COVID vaccines and their impact on children.

From holiday cheer to explosive national news, this episode dives deep:

In this explosive episode, we unpack the latest headlines shaking the military, politics, and public health:

Today's episode is packed with news, insights, and jaw-dropping revelations: ⚖️ Hoge files first Supreme Court tariff lawsuit – could cost taxpayers billions

M. Nathaniel Mead PhD returns to the podcast for an insightful discussion on scientific illiteracy, censorship, and the authoritative overreach that shaped the COVID-19 pandemic. What key information was dismissed, downplayed, or distorted by mainstream institutions? Press play to see for yourself… Nathan is a public health researcher, author, editor, educator, biomedical heretic, and McCullough Foundation Scholar. His writing has appeared in publications such as Natural Health, Utne Reader, American Health, and Integrative Cancer Therapies. Over the last several months, he has published a series of deeply researched papers analyzing the efficacy, safety, and long-term implications of the COVID-19 modified mRNA vaccines. In this conversation, we unpack: The tactics used to suppress alternative scientific viewpoints. How widespread scientific illiteracy fueled confusion and misinformation. Psychological control mechanisms amplified by AI and social media. The challenges faced by independent researchers questioning dominant narratives. To keep up with Mark online, connect with him on LinkedIn and X. He is also a McCullough Foundation Scholar at: @McCulloughFund Episode also available on Apple Podcasts: http://apple.co/30PvU9C

TWiV explains the Nobel Prize-winning discovery of pre-mRNA splicing, and engineering bacteriophage to deliver proteins to the human intestine. Hosts: Vincent Racaniello, Kathy Spindler, and Brianne Barker Subscribe (free): Apple Podcasts, RSS, email Become a patron of TWiV! Links for this episode Support science education at MicrobeTV Immune 100 live at the Incubator Spliced segments of adenovirus mRNA (PNAS) An amazing sequence in adenovirus mRNA (Cell) Nobel Prize for mRNA splicing (Nobel) A predominant undecanucleotide in adenovirus late mRNAs (Cell) Splicing RNA with Phillip A. Sharp (ASM) Protein production in the gut by engineered phage (Nat Biotech) Engineered phage T4 (Curr Op Virol) Timestamps by Jolene Ramsey. Thanks! Weekly Picks Brianne – Can You Identify These Lines from Classic SciFi Novels? Kathy – Saturday Morning Physics, Photograph 51 and JCE article Rich – Wikipedia:Wiki Science Competition 2025 in the United States Jolene – Data visualization workshop Vincent – Transformer: The Deep Chemistry of Life and Death by Nick Lane Intro music is by Ronald Jenkees Send your virology questions and comments to twiv@microbe.tv Content in this podcast should not be construed as medical advice.

In his weekly clinical update, Dr. Griffin and Vincent Racaniello wish everyone a Happy Thanksgiving and then decry appointment of the Louisiana State surgeon general as deputy chief of the CDC, the 3 children's deaths during this fall's pertussis outbreak, the Marburg virus outbreak in Ethiopia, results of the phase 1 safety trial for the novel poliovirus vaccines nOPV1 and nOPV3, and the first human death from H5N5 influenza virus infection in the US this fall, before Dr. Griffin deep dives into recent statistics on the measles epidemic, RSV, influenza and SARS-CoV-2 infections, the Wasterwater Scan dashboard, Johns Hopkins measles tracker, effectiveness of the cell or egg based flu or the mRNA vaccines, immunogenicity and efficacy of updated COVID-19 vaccines, where to find PEMGARDA, how to access and pay for Paxlovid, long COVID treatment center, where to go for answers to your long COVID questions, immune and cognitive dysfunction during long COVID and contacting your federal government representative to stop the assault on science and biomedical research. Subscribe (free): Apple Podcasts, RSS, email Become a patron of TWiV! Links for this episode Anti-science Movement: Deputy director of CDC (X:Louisiana Office of the Surgeon General) CDC's new deputy director is vocal critic of vaccines, advocated for ivermectin (CIDRAP) Whooping cough cases on the rise in Texas (FOX4: KDFW) Third infant in Kentucky dies of whooping cough as national cases stay high for second year in a row (CIDRAP) More than 25,000 whooping cough cases reported this year as Kentucky records 3rd infant death (ABC News) Vaccination Coverage and Exemptions among Kindergartners (CDC: SchoolVaxView) Effects of human papillomavirus (HPV) vaccination programmes on community rates of HPV‐related disease and harms from vaccination (Cochrane Library) Marburg Outbreak in Ethiopia: Current Situation (CDC: Marburg Virus Disease) Safety and immunogenicity of novel live attenuated type 1 and type 3 oral poliomyelitis vaccines in healthy adults in the USA: a first-in-human, observer-masked, multicentre, phase 1 randomised controlled trial (LANCET: Infectious Diseases) Washington state resident believed to be the first to die from a rare strain of bird flu (AP News) Wastewater for measles (WasterWater Scan) Measles cases and outbreaks (CDC Rubeola) Tracking Measles Cases in the U.S. (Johns Hopkins) Measles vaccine recommendations from NYP (jpg) Weekly measles and rubella monitoring (Government of Canada) Measles (WHO) Get the FACTS about measles (NY State Department of Health) Measles (CDC Measles (Rubeola)) Measles vaccine (CDC Measles (Rubeola)) Presumptive evidence of measles immunity (CDC) Contraindications and precautions to measles vaccination (CDC) Adverse events associated with childhood vaccines: evidence bearing on causality (NLM) Measles Vaccination: Know the Facts (ISDA: Infectious Diseases Society of America) Deaths following vaccination: what does the evidence show (Vaccine) Influenza: Waste water scan for 11 pathogens (WastewaterSCan) US respiratory virus activity (CDC Respiratory Illnesses) Respiratory virus activity levels (CDC Respiratory Illnesses) Weekly surveillance report: clift notes (CDC FluView) Superior Effectiveness and Estimated Public Health Impact of Cell- Versus Egg-Based Influenza Vaccines in Children and Adults During the US 2023–2024 Season (Infectious Diseases and Therapy) Efficacy, Immunogenicity, and Safety of Modified mRNA Influenza Vaccine(NEJM) ACIP Recommendations Summary (CDC: Influenza) Types of Influenza Viruses (CDC: Influenza (flu)) Influenza Vaccine Composition for the 2025-2026 U.S. Influenza Season (FDA) RSV: Waste water scan for 11 pathogens (WastewaterSCan) Respiratory Diseases (Yale School of Public Health) US respiratory virus activity (CDC Respiratory Illnesses) RSV-Network (CDC Respiratory Syncytial virus Infection) Vaccines for Adults (CDC: Respiratory Syncytial Virus Infection (RSV)) Economic Analysis of Protein Subunit and mRNA RSV Vaccination in Adults aged 50-59 Years (CDC: ACIP) Estimating Risk of Guillain-Barré Syndrome in US Medicare-Enrolled Older Adults Following Medically Attended Respiratory Syncytial Virus Disease (CID) FDA Requires Guillain-Barré Syndrome (GBS) Warning in the Prescribing Information for RSV Vaccines Abrysvo and Arexvy: FDA Safety Communication (FDA) Brag Sets Off a Chain Reaction — Dr. Oz Takes the Bait, But Fumbles the Math, and Starts Unraveling Mid-Interview (Atlanta BlackStar) Waste water scan for 11 pathogens (WastewaterSCan) COVID-19 deaths (CDC) Respiratory Illnesses Data Channel (CDC: Respiratory Illnesses) COVID-19 national and regional trends (CDC) COVID-19 variant tracker (CDC) SARS-CoV-2 genomes galore (Nextstrain) Antigenic and Virological Characteristics of SARS-CoV-2 Variant BA.3.2, XFG, and NB.1.8.1 (bioRxiV) Effectiveness of the BNT162b2 and mRNA-1273 JN.1-adapted vaccines against COVID-19-associated hospitalisation and death: a Danish, nationwide, register-based, cohort study (LANCET: Infectious Diseases) Immunogenicity of JN.1- and KP.2-Encoding mRNA COVID-19 Vaccines Against JN.1 Subvariants in Adult Participants (OFID) SARS-CoV-2 vaccination and myositis in Norway and Sweden (Rheumatology) Where to get pemgarda (Pemgarda) EUA for the pre-exposure prophylaxis of COVID-19 (INVIYD) Infusion center (Prime Fusions) CDC Quarantine guidelines (CDC) NIH COVID-19 treatment guidelines (NIH) Drug interaction checker (University of Liverpool) Help your eligible patients access PAXLOVID with the PAXCESS Patient Support Program (Pfizer Pro) Understanding Coverage Options (PAXCESS) Infectious Disease Society guidelines for treatment and management (ID Society) Molnupiravir safety and efficacy (JMV) Convalescent plasma recommendation for immunocompromised (ID Society) What to do when sick with a respiratory virus (CDC) Managing healthcare staffing shortages (CDC) Anticoagulation guidelines (hematology.org) Daniel Griffin's evidence based medical practices for long COVID (OFID) Long COVID hotline (Columbia : Columbia University Irving Medical Center) The answers: Long COVID Digitally Assessed Long COVID Symptomatology Is Associated With Lymphocyte Mitochondrial Dysfunction and Altered Immune Potential (OFID) Evaluation of Interventions for Cognitive Symptoms in Long COVID (JAMA Neurology) Reaching out to US house representative Letters read on TWiV 1274 Dr. Griffin's COVID treatment summary (pdf) Timestamps by Jolene Ramsey. Thanks! Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to daniel@microbe.tv Content in this podcast should not be construed as medical advice.

Send us a textGood morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today we dive into some of the most significant and exciting advancements shaping the industry.Let's start with a breakthrough coming out of recent clinical trials. A novel approach to treating Alzheimer's disease is making waves. Researchers have been focusing on a monoclonal antibody designed to target amyloid-beta plaques in the brains of patients suffering from this debilitating condition. The latest Phase 3 trial results have shown a promising reduction in cognitive decline among participants, offering a glimmer of hope for millions affected by Alzheimer's worldwide. The study, conducted over 18 months, involved more than 1,500 patients and demonstrated a statistically significant slowing of disease progression compared to placebo. This could mark a pivotal moment in Alzheimer's treatment, shifting the paradigm from symptomatic relief to disease modification.In regulatory news, the FDA has granted approval to a new gene therapy for hemophilia B. This therapy, developed using cutting-edge CRISPR technology, offers a potential cure for patients who have long relied on regular infusions to manage their bleeding disorder. By directly editing the genes responsible for clotting factor production, this therapy can potentially provide long-term relief with just a single administration. The approval follows extensive clinical trials that showed sustained increases in clotting factor levels and a dramatic reduction in bleeding episodes among participants. This development not only underscores the growing impact of genomic medicine but also highlights the regulatory body's commitment to advancing innovative treatments that meet unmet medical needs.Shifting focus, there's an intriguing trend emerging in oncology drug development. The industry is increasingly adopting personalized medicine approaches, tailoring treatments based on individual genetic profiles. This shift is particularly evident in the rise of targeted therapies and combination regimens designed to tackle cancer at its genetic roots. A recent study demonstrated how combining targeted therapies with immune checkpoint inhibitors can enhance treatment efficacy in certain types of cancer, such as melanoma and non-small cell lung cancer. By understanding the specific mutations driving tumor growth and leveraging the body's immune response, these combinations are setting new standards for cancer care.In another significant development, researchers have unveiled promising results from an innovative mRNA vaccine trial aimed at combating infectious diseases beyond COVID-19. The technology, which gained prominence during the pandemic, is now being applied to other viral threats like influenza and RSV. Early-phase clinical trials have shown robust immune responses and favorable safety profiles, suggesting mRNA vaccines could soon revolutionize how we approach vaccination for a variety of pathogens. This versatility and rapid development timeline make mRNA platforms particularly attractive for addressing emerging infectious diseases swiftly.Meanwhile, a new study has raised awareness about antibiotic resistance—a growing concern globally. Scientists have developed an advanced diagnostic tool capable of rapidly identifying bacterial infections and their resistance profiles within hours instead of days. This innovation can significantly impact how clinicians prescribe antibiotics, ensuring targeted treatments that minimize resistance development. By providing real-time insights into bacterial genetics and resistance mechanisms, this tool empowers healthcare providers to make informed decisions that preserve antibiotic efficacy for future generations.Lastly, let's toSupport the show

Biontech und Hytron betreiben medizinische Spitzenforschung. Grund genug ihnen einen Besuch abzustatten und über den aktuellen Stand der mRNA Forschung zu sprechen. So geht es in dieser Folge um DNA-Drucker, ein medizinisches Erfolgsjahrzehnt und die Frage wer manchmal die intensivere Betreuung braucht: Patienten oder deren Familie.

TODAY ON THE ROBERT SCOTT BELL SHOW: Vaccine Injury Shock, Boston Rejects CDC, Kim Elia, Homeopathic Education, Rhododendron Ferrugineum, Court Upholds Mandates, Dr. Nathaniel Mead, mRNA dangers, ShamWow Guy for Congress, and MORE! Vaccine Injury Shock, Boston Rejects CDC, Kim Elia, Homeopathic Education, Rhododendron Ferrugineum, Court Upholds Mandates, ShamWow Guy for Congress, and MORE! https://boxcast.tv/view/vaccine-injury-shock-boston-rejects-cdc-kim-elia-homeopathic-education-dr-nathaniel-mead-mrna-dangers---the-rsb-show-11-25-25-p2oshy2so05siatbvhgu Purpose and Character The use of copyrighted material on the website is for non-commercial, educational purposes, and is intended to provide benefit to the public through information, critique, teaching, scholarship, or research. Nature of Copyrighted Material Weensure that the copyrighted material used is for supplementary and illustrative purposes and that it contributes significantly to the user's understanding of the content in a non-detrimental way to the commercial value of the original content. Amount and Substantiality Our website uses only the necessary amount of copyrighted material to achieve the intended purpose and does not substitute for the original market of the copyrighted works. Effect on Market Value The use of copyrighted material on our website does not in any way diminish or affect the market value of the original work. We believe that our use constitutes a 'fair use' of any such copyrighted material as provided for in section 107 of the U.S. Copyright Law. If you believe that any content on the website violates your copyright, please contact us providing the necessary information, and we will take appropriate action to address your concern.

The NHS approves a groundbreaking new “living drug” for aggressive leukaemia, offering fresh hope for patients whose cancer has returned or resisted treatment — and marking a major win for London's life sciences sector. Plus, UCL and Royal Free researchers push forward with greener, cheaper ways to manufacture next-gen cell therapies.We also look at how UK scientists are repurposing Covid-era mRNA tech to protect against snake venom, and why new climate data shows Europe's winters — including London's — are becoming wetter far faster than models predicted.Later in the episode, we speak to Prehistoric Planet: Ice Age executive producer Mike Gunton about snow sloths, Ice Age surprises, and the lessons ancient climate change still holds today.Also in this episode:A new germanium-based quantum material sets a record for hole mobility — and could support faster, cooler and more efficient future chipsGhost of Yotei drops its biggest update yet, including New Game Plus and a 120Hz mode for PS5 and PS5 ProNintendo rolls out a stability patch for both Switch and Switch 2, fixing data-transfer and Bluetooth issuesFor all the latest news, head to standard.co.uk. Hosted on Acast. See acast.com/privacy for more information.

Dr. Jeffrey Kopin, Chief Medical Officer for Northwestern Medicine Catherine Gratz Griffin Lake Forest Hospital, joins John Williams to talk about why you should go for a brief walk after having your Thanksgiving meal, why he suggests getting a COVID shot and a flu shot in separate arms, Pfizer’s mRNA flu shot outperforming the standard flu vaccine in […]

Dr. Jeffrey Kopin, Chief Medical Officer for Northwestern Medicine Catherine Gratz Griffin Lake Forest Hospital, joins John Williams to talk about why you should go for a brief walk after having your Thanksgiving meal, why he suggests getting a COVID shot and a flu shot in separate arms, Pfizer’s mRNA flu shot outperforming the standard flu vaccine in […]

Dr. Jeffrey Kopin, Chief Medical Officer for Northwestern Medicine Catherine Gratz Griffin Lake Forest Hospital, joins John Williams to talk about why you should go for a brief walk after having your Thanksgiving meal, why he suggests getting a COVID shot and a flu shot in separate arms, Pfizer’s mRNA flu shot outperforming the standard flu vaccine in […]

The McCullough Report with Dr. Peter McCullough – A wide-ranging conversation explores concerns about vaccine safety, genetic effects, public-health transparency, and medical autonomy. The discussion highlights disputed interpretations of mRNA technology, the role of federal agencies, and calls for open data, independent investigation, and renewed trust between patients and physicians while examining cultural, ethical, and...

The McCullough Report with Dr. Peter McCullough – A wide-ranging conversation explores concerns about vaccine safety, genetic effects, public-health transparency, and medical autonomy. The discussion highlights disputed interpretations of mRNA technology, the role of federal agencies, and calls for open data, independent investigation, and renewed trust between patients and physicians while examining cultural, ethical, and...

The future of food is becoming more uncertain every day. Scientists are modifying the foods you eat, and growing meat in a lab, all while working to reduce (or ban) the consumption of real meat.  They're editing the genetic material of common foods like corn, apples and potatoes to promote infertility and stop foods from browning. They're adding new chemicals without proper testing and calling them safe.... But if you know how to play their game, you can avoid all of these toxic foods and access real health foods the way God intended.   TOPICS DISCUSSED: How GMO foods may be affecting your genes and DNA What food scientists are doing to your food mRNA vaccines being put into foods The shocking truth of food modification  Lab grown meat, mRNA based pesticides, and genetically modified insects How you can reclaim real, ancient food   Leave us a Review: https://www.reversablepod.com/review   Need help with your gut? Visit my website gutsolution.ca to join a program: Get help now   Contact us: reversablepod.com/tips    FIND ME ON SOCIAL MEDIA: Instagram  Facebook  YouTube

Send us a textGood morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we dive into a series of significant stories shaping the future of healthcare, from innovative financing strategies to groundbreaking scientific advancements.The biotech industry in 2025 has experienced a notable shift in funding strategies, particularly through the rising trend of royalty financing. This approach, involving the exchange of future drug revenue for immediate capital, has surged to approximately $3.5 billion in disclosed upfront volume in just the first half of the year. According to health economist Julien Willard, this represents a transformative shift from a niche option to a mainstream strategy amid challenging equity and credit markets. Royalty financing provides biotech companies with a lifeline, allowing them to avoid the pitfalls of equity dilution or high-interest debt while retaining control over their clinical developments. Firms like Royalty Pharma and Healthcare Royalty Partners are at the forefront, offering upfront cash for future sales royalties, typically ranging from 2.5% to 7.5%.This trend has accelerated due to economic pressures like low stock valuations and rising interest rates, making traditional funding routes less viable. A closer look at this year's deals reveals a cautious approach among investors, who are focusing on phase 3 trials or candidates awaiting FDA approval rather than early-stage assets. Oncology takes center stage as the leading therapeutic area, accounting for about 70% of total disclosed funding, thanks to its potential for large revenue streams. Other areas like rare genetic diseases and immunology also attract significant attention.Interestingly, even large pharmaceutical companies such as Biogen have ventured into royalty financing—an unconventional move for well-capitalized firms. Biogen's collaboration with Royalty Pharma for lupus drug development illustrates innovative financial engineering by transferring clinical trial risk through milestone-tied payments. As this strategy gains traction globally, especially in cash-strapped regions like Asia, it serves as a crucial tool for companies prioritizing survival and continued innovation amidst financial uncertainties.Turning now to regulatory dynamics and strategic shifts within the industry. The legal controversy between GSK's subsidiary Tesaro and AnaptysBio over Jemperli highlights complexities in collaborative agreements within drug development. Such disputes could reshape how companies negotiate intellectual property rights and revenue sharing in future co-development deals.The FDA's investigation into Takeda's Adzynma following a pediatric patient's death underscores the critical role of post-market surveillance in drug safety. This incident could potentially impact Takeda's market position while emphasizing the need for robust adverse event monitoring systems across biopharmaceutical firms.In Australia, the government's decision to block Cosette's proposed $430 million acquisition of Mayne Pharma reflects increasing scrutiny on foreign investments in healthcare companies, prioritizing national interest. This move signals a growing trend that could reshape global M&A strategies within the sector.Meanwhile, Moderna's strategic financial maneuvering is noteworthy. By securing a $1.5 billion loan aimed at supporting its commercial and R&D endeavors with an eye on breaking even by 2028, Moderna demonstrates its commitment to diversifying its mRNA technology applications beyond COVID-19 vaccines—a move likely to influence innovation trajectories across biotech landscapes. Additionally, Moderna's decision to discontinue three clinical mRNA programs showcases strategic pipeline management amidSupport the show

Program notes:1:25 mRNA flu vaccine2:25 Phase three trial3:25 Preventing infection with a respiratory virus4:25 Prophylaxis with NSAID?4:45 Umbrella review of acetaminophen in pregnancy, ASD and ADHD5:42 Confidence was low to critically low6:45 Other factors such as environmental exposures7:22 Increasing potassium to prevent heart arrythmias8:33 Increase with supplements or dietary advice9:18 Canceling funding for clinical trials10:18 In the process of receiving interventions11:18 Can't not analyze 12:15 End

Dr Joseph Sansone joins Ann Vandersteel and Dr Jane Ruby to discuss his battle to get the mRNA shots pulled off the market.

Send us a textGood morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a landscape marked by significant scientific advancements, regulatory approvals, and strategic shifts that are reshaping the industry.Starting with Regeneron, the company's ophthalmic drug Eylea HD has recently secured two FDA approvals. These endorsements not only grant a new indication but also introduce a more flexible dosing regimen. This positions Eylea HD competitively against Roche's Vabysmo, highlighting the importance of regulatory navigation and strategic positioning in the pharmaceutical sector. These approvals come after extensive negotiations with both the FDA and third-party manufacturers, emphasizing the intricate processes involved in bringing a drug to market.In oncology, Bayer has achieved an accelerated FDA approval for Hyrnuo, a treatment targeting HER2-mutated non-small cell lung cancer. This move allows Bayer to challenge Boehringer Ingelheim's Hernexeos, underscoring the fiercely competitive nature of the oncology market. Such advancements are driven by innovative treatments that address specific genetic mutations in cancer patients, reflecting a broader trend towards precision medicine.Meanwhile, Moderna is investing heavily in mRNA production capabilities with a new $140 million facility in Norwood, Massachusetts. This development underscores Moderna's commitment to mRNA technology, which gained significant attention during the COVID-19 pandemic. The facility aims to establish robust domestic manufacturing infrastructures to mitigate supply chain vulnerabilities—a critical move considering recent global disruptions.Novartis is also making headlines with its plans for a flagship production hub in North Carolina. This expansion is expected to create 700 jobs and expand its manufacturing footprint by 700,000 square feet, highlighting Novartis's strategic emphasis on scaling up operations to meet growing demands and enhance production efficiency.In another strategic collaboration, Antheia has joined forces with Teva's TAPI division to enhance the commercialization prospects for its biosynthetic pipeline. This alliance marks a significant step toward advancing biologically derived pharmaceuticals, promising to revolutionize drug production through more sustainable and scalable alternatives to traditional chemical synthesis.On the regulatory front, Merck has received broad EU approval for a subcutaneous formulation of Keytruda. This development could significantly expand Keytruda's market reach across Europe, demonstrating how regulatory agility can extend drug lifecycles and maximize therapeutic impact across diverse patient populations.Compliance challenges remain prevalent, as illustrated by Pfizer and Tris Pharma's settlement of allegations related to ADHD medication Quillivant's quality control issues for $41.5 million. This case highlights ongoing efforts to ensure stringent quality standards within pharmaceutical manufacturing processes.Abbott is expanding its diagnostics portfolio through a $23 billion acquisition of Exact Sciences, known for its Cologuard colorectal cancer test. This acquisition indicates a strategic shift towards enhancing diagnostic capabilities alongside therapeutic offerings—a trend increasingly evident in holistic healthcare solutions.GSK is embarking on a $7 billion collaboration with biotechs Quotient and Profound through Flagship Pioneering. This partnership aims to leverage novel protein and genomic technologies to drive innovation in drug discovery and development, illustrating the industry's focus on integrating advanced biotechnological insights into traditional pharmaceutical frameworks.These developments collectively underscore crSupport the show

“Welcome, welcome our wonderful audience!” Dr. Peter Breggin opened The Breggin Hour this week, talking about the effects of his stroke and about our efforts to seek rehabilitation, offering the best chance of optimizing recovery from brain damage. The indomitable Karen Kingston, who has been exposing the dangers of the mRNA vaccines for over five years, joined us. Peter spent a portion of the hour further detailing his experience of receiving treatment at the AVIV clinic, which offers a very specialized program of Hyperbaric Oxygen Treatment (HBOT). Peter made a comment at some point in the program, stating we must “muster great courage equal to our fear…” That phrase sums up for me my husband's attitude since his stroke. He is forging ahead, determined to embrace with both arms the work required to heal. During the third segment, we lost audio with Karen Kingston, so Peter and I finished up discussing artificial intelligence, and Karen's point that AI has been introduced just at a time when the human population is suffering from unprecedented amounts of neurological damage, from the mRNA vaccines as well as from other sources. She pointed out that the creators of the AI programs being used were doing the thinking—the cognitive work—for the individuals using it, which means humans are doing less independent thinking and creating increasing dependency upon outside sources. The neuropsychiatric damage done by mRNA vaccines is being clearly identified. Peter was a coauthor, along with other noted experts, of a recently published scientific paper: “Association Between COVID-19 Vaccination and Neuropsychiatric Conditions,” published in the International Journal of Innovative Research in Medical Science. The paper details over 58 profound neurological adverse effects resulting from mRNA vaccines. Dr. James Thorp spearheaded this research as lead author. The show was a mix of the deeply personal and an examination of some of the threats to humanity's future, with some sweet moments between Peter and Ginger.

Dr Joseph Sansone joins me live to unpack the latest development in his Florida mRNA court case after the 1DCA dismissed his appeal and pushed the fight back into the trial court. His amended complaint brings together months of studies, affidavits, medical documentation and official statements that challenge the ongoing distribution of mRNA injections in the state. This episode walks through why the case is intensifying and what this pivotal shift means for the battle ahead.Supermassive Black Coffee is crafted from organic, gourmet beans fire-roasted in an antique Victorian-era roaster, delivering the rich, smooth, non-acidic taste that reminds you this is how coffee was always meant to be. Use code JEFF50 for 50% off your first order. https://supermassiveblackcoffee.com/?ref=JEFFFollow Dr Joseph Sansone on Pickax: https://pickax.com/phdsansoneFollow Jeff Dornik on Pickax: https://pickax.com/jeffdornikTune into The Jeff Dornik Show LIVE every Tuesday and Thursday at 1pm ET. Subscribe on Rumble and never miss a show. https://rumble.com/c/jeffdornikBig Tech is silencing truth while farming your data to feed the machine. That's why I built Pickax… a free speech platform that puts power back in your hands and your voice beyond their reach. Sign up today:https://pickax.com/?referralCode=y7wxvwq&refSource=copy

America Out Loud PULSE with Dr. Peter McCullough and Malcolm Out Loud – I recently had a sperm analysis done, and the sample showed normal ranges. Could it be a signal that spike and mRNA aren't in me anymore? Is it true that iodine supplement increases the mRNA decay rate? Please spend some time talking about Recharge with Methylene Blue, as I am intrigued by this product that everyone is talking about...

In Tests hat sich der mRNA-Impfstoff als wirksamer gegen Grippe erwiesen als herkömmlicher Impfstoff, es gab aber mehr Impfreaktionen. Im Notfall kann er schnell hergestellt werden. Denn Fachleute beobachten mit Sorge die Verbreitung der Vogelgrippe. Budde, Joachim www.deutschlandfunk.de, Forschung aktuell

Seynsche, Monika www.deutschlandfunk.de, Forschung aktuell

From CFTR modulators to gene therapy, what's next in cystic fibrosis research? Peter Mogayzel examines future therapies, ongoing access challenges, and the crucial link between advocacy, innovation, and global health equity in cystic fibrosis care. Timestamps: 00:00 – Introduction 01:05 - CFTR modulators 03:35 – Anti-inflammatory drugs 04:18 – mRNA therapy 04:53 – Side effects 07:13 – Access to care 08:37 – Exercise 10:00 – Final thoughts

This week, we look at new research on potassium optimization in patients with defibrillators, reducing antihypertensive therapy in nursing homes, an mRNA influenza vaccine, and belzutifan for rare neuroendocrine tumors. We review long QT syndrome and present a case of abnormal behavior and seizures in a young man. We also explore perspectives on primary care reform, tobacco cessation in HIV and tuberculosis care, corporate control in health care, and the simple power of compassion with ice cream.

What happens when mRNA meets lipid nanoparticles? Sparks fly—and science wins. This dynamic duo is behind breakthroughs from game-changing vaccines to strategies for silencing stubborn viruses.Join Dodi and Conor as they sit down with Professor Sharon Lewin, a global leader in HIV research, to explore how this partnership could transform treatment and rewrite the future of medicine.Smart science, big ideas—don't miss this episode of Discovery Matters, brought to you by Cytiva.

Authors Drs. Jessica Ross and Alissa Cooper share insights into their JCO PO article, "Clinical and Pathologic Landscapes of Delta-Like Ligand 3 and Seizure-Related Homolog Protein 6 Expression in Neuroendocrine Carcinomas"  Host Dr. Rafeh Naqash and Drs. Ross and Cooper discuss the landscape of Delta-like ligand 3 (DLL3) and seizure-related homolog protein 6 (SEZ6) across NECs from eight different primary sites. TRANSCRIPT Dr. Rafeh Naqash: Hello and welcome to JCO Precision Oncology Conversations, where we bring you engaging conversations with authors of clinically relevant and highly significant JCO PO articles. I'm your host, Dr. Rafeh Naqash, podcast editor for JCO PO and an Associate Professor at the OU Health Stephenson Cancer Center. Today, I'm excited to be joined by Dr. Jessica Ross, third-year medical oncology fellow at the Memorial Sloan Kettering Cancer Center, as well as Dr. Alissa Cooper, thoracic medical oncologist at the Dana-Farber Cancer Institute and instructor in medicine at Harvard Medical School. Both are first and last authors of the JCO Precision Oncology article entitled "Clinical and Pathologic Landscapes of Delta-like Ligand 3 and Seizure-Related Homolog Protein 6 or SEZ6 Protein Expression in Neuroendocrine Carcinomas." At the time of this recording, our guest disclosures will be linked in the transcript. Jessica and Alissa, welcome to our podcast, and thank you for joining us today. Dr. Jessica Ross: Thanks very much for having us. Dr. Alissa Cooper: Thank you. Excited to be here. Dr. Rafeh Naqash: It's interesting, a couple of days before I decided to choose this article, one of my GI oncology colleagues actually asked me two questions. He said, "Rafeh, do you know how you define DLL3 positivity? And what is the status of DLL3 positivity in GI cancers, GI neuroendocrine carcinomas?" The first thing I looked up was this JCO article from Martin Wermke. You might have seen it as well, on obrixtamig, a phase 1 study, a DLL3 bi-specific T-cell engager. And they had some definitions there, and then this article came along, and I was really excited that it kind of fell right in place of trying to understand the IHC landscape of two very interesting targets. Since we have a very broad and diverse audience, especially community oncologists, trainees, and of course academic clinicians and some people who are very interested in genomics, we'll try to make things easy to understand. So my first question for you, Jessica, is: what is DLL3 and SEZ6 and why are they important in neuroendocrine carcinomas? Dr. Jessica Ross: Yeah, good question. So, DLL3, or delta-like ligand 3, is a protein that is expressed preferentially on the tumor cell surface of neuroendocrine carcinomas as opposed to normal tissue. It is a downstream target of ASCL1, and it's involved in neuroendocrine differentiation, and it's an appealing drug target because it is preferentially expressed on tumor cell surfaces. And so, it's a protein, and there are several drugs in development targeting this protein, and then Tarlatamab is an approved bi-specific T-cell engager for the treatment of extensive-stage small cell lung cancer in the second line. SEZ6, or seizure-like homolog protein 6, is a protein also expressed on neuroendocrine carcinoma cell surface. Interestingly, so it's expressed on neuronal cells, but its exact role in neuroendocrine carcinomas and oncogenesis is actually pretty poorly understood, but it was identified as an appealing drug target because, similarly to DLL3, it's preferentially expressed on the tumor cell surface. And so this has also emerged as an appealing drug target, and there are drugs in development, including antibody-drug conjugates, targeting this protein for that reason. Dr. Alissa Cooper: Over the last 10 to 15 years or so, there's been an increasing focus on precision oncology, finding specific targets that actually drive the cancer to grow, not just within lung cancer but in multiple other primary cancers. But specifically, at least speaking from a thoracic oncology perspective, the field of non-small cell lung cancer has completely exploded over the past 15 years with the discovery of driver oncogenes and then matched targeted therapies. Within the field of neuroendocrine carcinomas, including small cell lung cancer but also other high-grade neuroendocrine carcinomas, there has not been the same sort of progress in terms of identifying targets with matched therapies. And up until recently, we've sort of been treating these neuroendocrine malignancies kind of as a monolithic disease process. And so recently, there's been sort of an explosion of research across the country and multiple laboratories, multiple people converging on the same open questions about why might patients with specific tumor biologies have different kind of responses to different therapies. And so first this came from, you know, why some patients might have a good response to chemo and immunotherapy, which is the first-line approved therapy for small cell lung cancer, and we also sort of extrapolate that to other high-grade neuroendocrine carcinomas. What's the characteristic of that tumor biology? And at the same time, what are other targets that might be identifiable? Just as Jesse was saying, they're expressed on the cell surface, they're not necessarily expressed in normal tissue. Might this be a strategy to sort of move forward and create smarter therapies for our patients and therefore move really into a personalized era for treatment for each patient? And that's really driving, I think, a lot of the synthesis of this work of not only the development of multiple new therapies, but really understanding which tumor might be the best fit for which therapy. Dr. Rafeh Naqash: Thank you for that explanation, Alissa. And as you mentioned, these are emerging targets, some more further along in the process with approved drugs, especially Tarlatamab. And obviously, DLL3 was something identified several years back, but drug development does take time, and readout for clinical trials takes time. Could you, for the sake of our audience, try to talk briefly about the excitement around Tarlatamab in small cell lung cancer, especially data that has led to the FDA approval in the last year, year and a half? Dr. Alissa Cooper: Sure. Yeah, it's really been an explosion of excitement over, as you're saying, the last couple of years, and work really led by our mentor, Charlie Rudin, had identified DLL3 as an exciting target for small cell lung cancer specifically but also potentially other high-grade neuroendocrine malignancies. Tarlatamab is a DLL3-targeting bi-specific T-cell engager, which targets DLL3 on the small cell lung cancer cells as well as CD3 on T cells. And the idea is to sort of introduce the cancer to the immune system, circumventing the need for MHC class antigen presentation, which that machinery is typically not functional in small cell lung cancer, and so really allowing for an immunomodulatory response, which had not really been possible for most patients with small cell lung cancer prior to this. Tarlatamab was tested in a phase 2 registrational trial of about 100 patients and demonstrated a response rate of 40%, which was very exciting, especially compared with other standard therapies which were available for small cell lung cancer, which are typically cytotoxic therapies. But most excitingly, more than even the response rate, I think, in our minds was the durability of response. So patients whose disease did have a response to Tarlatamab could potentially have a durable response lasting a number of months or even over a year, which had previously not ever been seen in this in the relapsed/refractory setting for these patients. I think the challenge with small cell lung cancer and other high-grade neuroendocrine malignancies is that a response to therapy might be a bit easier to achieve, but it's that durability. The patient's tumors really come roaring back quite aggressively pretty quickly. And so this was sort of the most exciting prospect is that durability of response, that long potential overall survival tail of the curve really being lifted up. And then most recently at ASCO this year, Dr. Rudin presented the phase 3 randomized controlled trial which compared Tarlatamab to physician's choice of chemotherapy in a global study. And the choice of chemotherapy did vary depending on the part of the world that the patients were enrolled in, but in general, it was a really markedly positive study for response rate, for progression-free survival, and for overall survival. Really exciting results which really cemented Tarlatamab's place as the standard second-line therapy for patients with small cell lung cancer whose disease has progressed on first-line chemo-immunotherapy. So that has been very exciting. This drug was FDA approved in May of 2024, and so has been used extensively since then. I think the adoption has been pretty widespread, at least in the US, but now in this global trial that was just presented, and there was a corresponding New England Journal paper, I think really confirms that this is something we really hopefully can offer to most of our patients. And I think, as we all know, that this therapy or other therapies like it are also being tested potentially in the first-line setting. So there was data presented with Tarlatamab incorporated into the maintenance setting, which also showed exciting results, albeit in a phase 1 trial, but longer overall survival than we're used to seeing in this patient population. And we await results of the study that is incorporating Tarlatamab into the induction phase with chemotherapy as well. So all of this is extraordinarily exciting for our patients to sort of move the needle of how many patients we can keep alive, feeling functional, feeling well, for as long as possible. Dr. Rafeh Naqash: Very exciting session at ASCO. I was luckily one of the co-chairs for the session that Dr. Rudin presented it, and I remember somebody mentioning there was more progress seen in that session for small cell lung cancer than the last 30, 35 years for small cell, very exciting space and time to be in as far as small cell lung cancer. Now going to this project, Jessica, since you're the first author and Alissa's the last, I'm assuming there was a background conversation that you had with Alissa before you embarked on this project as an idea. So could you, again, for other trainees who are interested in doing research, and it's never easy to do research as a resident and a fellow when you have certain added responsibilities. Could you give us a little bit of a background on how this started and why you wanted to look at this question? Dr. Jessica Ross: Yeah, sure. So, as with many exciting research concepts, I think a lot of them are derived from the clinic. And so I think Alissa and I both see a good number of patients with small cell, large cell lung cancer, and then high-grade neuroendocrine carcinomas. And so I think this was really born out of a basic conversation of we have these drugs in development targeting these two proteins, DLL3 and SEZ6, but really what is the landscape of cancers that express these proteins and who are the patients that really might benefit from these exciting new therapies. And of course, there was some data out there, but sort of less than one would imagine in terms of, you know, neuroendocrine carcinomas can really come from anywhere in the body. And so when you're seeing a patient with small cell of the cervix, for example, like what are the chances that their cancer expresses DLL3 or expresses SEZ6? So it was really derived from this pragmatic, clinically oriented question that we had both found ourselves thinking about, and we were lucky enough at MSK, we had started systematically staining patients' tumors for DLL3, tumors that are high-grade neuroendocrine carcinomas, and then we had also more recently started staining for SEZ6 as well. And so we had this nice prospectively collected dataset with which to answer this question. Dr. Rafeh Naqash: Excellent. And Alissa, could you try to go into some of the details around which patients you chose, how many patients, what was the approach that you selected to collect the data for this project? Dr. Alissa Cooper: This is perhaps a strength but also maybe a limitation of this dataset is, as Jesse alluded to, our pathology colleagues are really the stars of this paper here because we were lucky enough at MSK that they were really forethinking. They are absolute experts in the field and really forward-thinking people in terms of what information might be needed in the future to drive treatment decision-making. And so, as Jesse had said, small cell lung cancer tumor samples reflexively are stained for DLL3 and SEZ6 at MSK if there's enough tumor tissue. The other high-grade neuroendocrine carcinomas, those stains are performed upon physician request. And so that is a bit of a mixed bag in terms of the tumor samples we were able to include in this dataset because, you know, upon physician request depends on a number of factors, but actually at MSK, a number of physicians were requesting these stains to be done on their patients with high-grade neuroendocrine cancers of of other histologies. So we looked at all tumor samples with a diagnosis of high-grade neuroendocrine carcinoma of any histology that were stained for these two stains of interest. You know, I can let Jesse talk a bit more about the methodology. She was really the driver of this project. Dr. Jessica Ross: Yeah, sure. So we had 124 tumor samples total. All of those were stained for DLL3, and then a little less than half, 53, were stained for SEZ6. As Alissa said, they were from any primary site. So about half of them were of lung origin, that was the most common primary site, but we included GI tract, head and neck, GU, GYN, even a few tumors of unknown origin. And again, that's because I think a lot of these trials are basket trials that are including different high-grade neuroendocrine carcinomas no matter the primary site. And so we really felt like it was important to be more comprehensive and inclusive in this study. And then, methodologically, we also defined positivity in terms of staining of these two proteins as anything greater than or equal to 1% staining. There's really not a defined consensus of positivity when it comes to these two novel targets and staining for these two proteins. But in the Tarlatamab trials, for some of the correlative work that's been done, they use that 1% cutoff, and we just felt like being consistent with that and also using a sort of more pragmatic yes/no cutoff would be more helpful for this analysis. Dr. Alissa Cooper: And that was a point of discussion, actually. We had contemplated multiple different schemas, actually, for how to define thresholds of positivity. And I know you brought up that question before, what does it mean to be DLL3 positive or DLL3 high? I think you were alluding to prior that there was a presentation of obrixtamig looking at extra-pulmonary neuroendocrine carcinomas, and they actually divvied up the results between DLL3 50% or greater versus DLL3 low under 50%. And they actually did demonstrate differential efficacy certainly, but also some differential safety as well, which is very provocative and that kind of analysis has not been presented for other novel therapies as far as I'm aware. I could be wrong, but as far as I'm aware, that was sort of the first time that we saw a systematic presentation of considering patients to be, quote unquote, "high" or "low" in these sort of novel targets. I think it is important because the label for Tarlatamab does not require any DLL3 expression at all, actually. So it's not hinging upon DLL3 expression. They depend on the fact that the vast majority of small cell lung cancer tumors do express DLL3, 85% to 90% is what's been demonstrated in a few studies. And so, there's not prerequisite testing needed in that regard, but maybe for these extra-pulmonary, other histology neuroendocrine carcinomas, maybe it does matter to some degree. Dr. Rafeh Naqash: Definitely agree that this evolving landscape of trying to understand whether an expression for something actually really does correlate with, whether it's an immune cell engager or an antibody-drug conjugate is a very evolving and dynamically moving space. And one of the questions that I was discussing with one of my friends was whether IHC positivity and the level of IHC positivity, as you've shown in one of those plots where you have double positive here on the right upper corner, you have the double negative towards the left lower, whether that somehow determines mRNA expression for DLL3. Obviously, that was not the question here that you were looking at, but it does kind of bring into question certain other aspects of correlations, expression versus IHC. Now going to the figures in this manuscript, very nicely done figures, very easy to understand because I've done the podcast for quite a bit now, and usually what I try to do first is go through the figures before I read the text, and and a lot of times it's hard to understand the figures without reading the text, but in your case, specifically the figures were very, very well done. Could you give us an overview, a quick overview of some of the important results, Jessica, as far as what you've highlighted in the manuscript? Dr. Jessica Ross: Sure. So I think the key takeaway is that, of the tumors in our cohort, the majority were positive for DLL3 and positive for SEZ6. So about 80% of them were positive for DLL3 and 80% were positive for SEZ6. About half of the tumors were stained for both proteins, and about 65% of those were positive as well. So I think if there's sort of one major takeaway, it's that when you're seeing a patient with a high-grade neuroendocrine carcinoma, the odds are that their tumor will express both of these proteins. And so that can sort of get your head thinking about what therapies they might be eligible for. And then we also did an analysis of some populations of interest. So for example, we know that non-neuroendocrine pathologies can transform into neuroendocrine tumors. And so we specifically looked at that subset of patients with transformed tumors, and those were also- the majority of them were positive, about three-quarters of them were positive for both of these two proteins. We looked at patients with brain met samples, again, about 70% were positive. And then I'd say the last sort of population of interest was we had a subset of 10 patients who had serial biopsies stained for either DLL3 or SEZ6 or both. In between the two samples, these patients were treated with chemotherapy. They were not treated with targeted therapy, but interestingly, in the majority of cases, the testing results were concordant, meaning if it was DLL3 positive to begin with, it tended to remain DLL3 positive after treatment. And so I think that's important as well as we think about, you know, a patient who maybe had DLL3 testing done before they received their induction chemo-IO, we can somewhat confidently say that they're probably still DLL3 positive after that treatment. And then finally, we did do a survival analysis among specifically the patients with lung neuroendocrine carcinomas. We looked at whether DLL3 expression affected progression-free survival on first-line platinum-etoposide, and then we looked at did it affect overall survival. And we found that it did not have an impact or the median progression-free survival was similar whether you were DLL3 positive or negative. But interestingly, with overall survival, we found that DLL3 positivity actually correlated with slightly improved overall survival. These were small numbers, and so, you know, I think we have to interpret this with caution, for sure, but it is interesting. I think there may be something to the fact that five of the patients who were DLL3 positive were treated with DLL3-targeting treatments. And so this made me think of, like in the breast cancer world, for example, if you have a patient with HER2-positive disease, it initially portended worse prognosis, more aggressive disease biology, but on the other hand, it opens the door for targeted treatments that actually now, at least with HER2-positive breast cancer, are associated with improved outcomes. And so I think that's one finding of interest as well. Dr. Rafeh Naqash: Definitely proof-of-concept findings here that you guys have in the manuscript. Alissa, if I may ask you, what is the next important step for a project like this in your mind? Dr. Alissa Cooper: Jesse has highlighted a couple of key findings that we hope to move forward with future investigative studies, not necessarily in a real-world setting, but maybe even in clinical trial settings or in collaboration with sponsors. Are these biomarkers predictive? Are they prognostic? You know, those are still- we have some nascent data, data has been brewing, but I think that we we still don't have the answers to those open questions, which I think are critically important for determining not only clinical treatment decision-making, but also our ability to understand sequencing of therapies, prioritization of therapies. I think a prospective, forward-looking project, piggybacking on that paired biopsy, you know, we had a very small subset of patients with paired biopsies, but a larger subset or cohort looking at paired biopsies where we can see is there evolution of these IHC expression, even mRNA expression, as you're saying, is there differential there? Are there selection pressures to targeted therapies? Is there upregulation or downregulation of targets in response not just to chemotherapy, but for example, for other sort of ADCs or bi-specific T-cell engagers? I think those are going to be critically important future studies which are going to be a bit challenging to do, but really important to figure out this key clinical question of sequencing, which we're all contemplating in our clinics day in and day out. If you have a patient, and these patients often can be sick quite quickly, they might have one shot of what's the next treatment that you're going to pick. We can't guarantee that every patient is going to get to see every therapy. How can you help to sort of answer the question of like what should you offer? So I think that's the key question sort of underlying any future work is how predictive or prognostic are these biomarkers? What translational or correlative studies can we do on the tissue to understand clinical treatment decision-making? I think those are the key things that will unfold in the next couple of years. Dr. Rafeh Naqash: The last question for you, Alissa, that I have is, you are fairly early in your career, and you've accomplished quite a lot. One of the most important things that comes out from this manuscript is your mentorship for somebody who is a fellow and who led this project. For other junior investigators, early-career investigators, how did you do this? How did you manage to do this, and how did you mentor Jessica on this project with some of the lessons that you learned along the way, the good and other things that would perhaps help other listeners as they try to mentor residents, trainees, which is one of the important things of what we do in our daily routine? Dr. Alissa Cooper: I appreciate you calling me accomplished. Um, I'm not sure how true that is, but I appreciate that. I didn't have to do a whole lot with this project because Jesse is an extraordinarily smart, driven, talented fellow who came up with a lot of the clinical questions and a lot of the research questions as well. And so this project was definitely a collaborative project on both of our ends. But I think what was helpful from both of our perspectives is from my perspective, I could kind of see that this was a gap in the literature that really, I think, from my work leading clinical trials and from treating patients with these kinds of cancers that I really hoped to answer. And so when I came to Jessica with this idea as sort of a project to complete, she was very eager to take it and run with it and also make it her own. You know, in terms of early mentorship, I have to admit this was the first project that I mentored, so it was a great learning experience for me as well because as an early-career clinician and researcher, you're used to having someone else looking over your shoulder to tell you, "Yes, this is a good journal target, here's what we can anticipate reviewers are going to say, here are other key collaborators we should include." Those kind of things about a project that don't always occur to you as you're sort of first starting out. And so all of that experience for me to be identifying those more upper-level management sort of questions was a really good learning experience for me. And of course, I was fantastically lucky to have a partner in Jesse, who is just a rising star. Dr. Jessica Ross: Thank you. Dr. Rafeh Naqash: Well, excellent. It sounds like the first of many other mentorship opportunities to come for you, Alissa. And Jessica, congratulations on your next step of joining and being faculty, hopefully, where you're training. Thank you again, both of you. This was very insightful. I definitely learned a lot after I reviewed the manuscript and read the manuscript. Hopefully, our listeners will feel the same. Perhaps we'll have more of your work being published in JCO PO subsequently. Dr. Alissa Cooper: Hope so. Thank you very much for the opportunity to chat today. Dr. Jessica Ross: Yes, thank you. This was great. Dr. Rafeh Naqash: Thank you for listening to JCO Precision Oncology Conversations. Don't forget to give us a rating or review and be sure to subscribe so as you never miss an episode. You can find all ASCO shows at asco.org/podcasts. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Disclosures: Dr. Alissa Jamie Cooper Honoraria Company: MJH Life Scienes, Ideology Health, Intellisphere LLC, MedStar Health, Physician's Education Resource, LLC,  Gilead Sciences, Regeneron, Daiichi Sankyo/Astra Zeneca, Novartis,  Research Funding: Merck, Roche, Monte Rosa Therapeutics, Abbvie, Amgen, Daiichi Sankyo/Astra Zeneca Travel, Accommodations, Expenses: Gilead Sciences

FREEDOM - HEALTH - HAPPINESSThis podcast is highly addictive and seriously good for your health.SUPPORT DOC MALIK To make sure you don't miss any episodes, have access to bonus content, back catalogue, and monthly Live Streams, please subscribe to either:The paid Spotify subscription here: ⁠⁠https://creators.spotify.com/pod/show/docmalik/subscribe⁠⁠ The paid Substack subscription here: ⁠⁠https://docmalik.substack.com/subscribe⁠⁠Thank you to all the new subscribers for your lovely messages and reviews! And a big thanks to my existing subscribers for sticking with me and supporting the show! ABOUT THIS CONVERSATION: In this episode I break down what I believe is one of the greatest scandals of our time. We were never given informed consent during COVID, and the truth is we still are not being given it today. From lockdowns to masking to the mRNA jab, from digital ID to central bank digital currencies, fifteen minute cities, net zero and the entire climate agenda, none of this has ever been honestly explained to the public. We have been managed, manipulated and coerced, not informed.This conversation was inspired by the work of Elizabeth Hart and a letter she shared with me that she sent to Professor Angus Dalgleish. Her research opened my eyes even further to how the medical profession, governments, PR machines, academic institutions and billionaire funded organisations shaped the narrative to manufacture compliance, not understanding.I talk openly about the failures of my own former profession, the coercion admitted by supposed experts, and the reality that anyone who pushed these products and still promotes them today has no place claiming leadership in any freedom movement.This is a call to clarity, a call to sovereignty, and a reminder that the entire system rests on our consent. Once we stop giving it, the spell breaks.This episode will challenge you, provoke you, and hopefully empower you to think differently.Enjoy the episode.See my substack for more info. Much love, as always.Doc MalikIMPORTANT INFORMATIONCONSULTATION SERVICEIn a world of rushed 7-minute consultations and endless referrals, I offer you something rare: time, context, and clear guidance.As your health advocate, I can help you:Understand your diagnosis and decode medical jargonDecide who to see: GP, specialist, osteopath, physio, accupuntcurist, homeopath etc?Break down treatment plans in plain, easy to understand non jargon EnglishPrepare for surgery, understand your risks, obtain true informed consent, and optimise yourself pre-op Recover from surgery, advise you how to heal faster and quicker and minimise post-op complicationsManage chronic illness with lifestyle, mindset, and dietary changesExplore holistic options that complement conventional careAsk better questions, and get real answersGet an unbiased second opinionReady to Take Control?If you're navigating a health concern, preparing for a big decision, or simply want to feel more confident in your path forward, I'd love to support you.Book here ⁠⁠ https://docmalik.com/consultations/ ⁠⁠Because it's your body, your life, and your future. Let's make sure you're informed and heard.SeagreenIf you want to support your health naturally, I highly recommend trying Sea Greens, a rich source of bioavailable iodine and trace minerals that nourish thyroid function, balance hormones, and provide a clean daily boost from wild ocean plants. Use the code DOCMALIK⁠⁠https://seagreens.shop/⁠⁠WaterpureI distill all my water for drinking, washing fruit and vegetables, and cooking. If you knew what was in tap water, so would you!⁠⁠https://waterpure.co.uk/docmalik BUY HERE TODAY⁠⁠Hunter & Gather FoodsSeed oils are inflammatory, toxic and nasty; eliminate them from your diet immediately. Check out the products from this great company⁠⁠https://hunterandgatherfoods.com/?ref=DOCHG BUY HERE TODAY⁠⁠Use DOCHG to get 10% OFF your purchase with Hunter & Gather Foods.

What if the tumor you're treating is already yesterday's news? In this riveting episode of Metabolic Matters, Dr. Nasha Winters sits down with Dr. John A. Catanzaro, NMD, PhD—Co-Founder and CEO of Neo7Bioscience and one of the leading innovators in personalized peptide therapeutics and molecular surveillance. With over 25 years at the intersection of clinical medicine, molecular biology, and translational research, Dr. Catanzaro specializes in understanding the real-time biology driving cancer, autoimmunity, chronic inflammation, degenerative disease, and mRNA-related injuries. His proprietary PBIMA® and REViSS® platforms analyze genomics, transcriptomics, proteomics, and AHI-driven analytics to design patient-specific peptide sequences tailored to each individual's molecular signature.Connect with Dr. John: WebsiteDr. John's XNeoScience XFacebookSubstack Dr. John LinkedInNeoScience LinkedInNeoScience YoutubeAbout Your HostI'm Dr. Nasha Winters, a global healthcare authority, best-selling author, and educator in the emerging field of integrative oncology and terrain-based cancer care. I host Metabolic Matters to explore the intersections between metabolism, medicine, and meaning.Subscribe, Share & ReviewIf you loved this conversation, please subscribe, rate, and share with a friend or clinician who needs to hear it.Support & Resources:Support Patient Grants: www.mtih.orgBook: The Metabolic Approach to CancerEducation Programs: www.metabolicregen.comSupplements: mitovida.comFollow on SocialsDr. Nasha on InstagramMetabolic Matters InstagramFacebookLinkedInTikTokYouTube Hosted on Acast. See acast.com/privacy for more information.

A sweeping conversation about how modern systems keep us nutritionally weak, spiritually dulled, and biologically confused — and how simply eating "food for humans" can reverse disease, restore vitality, and reconnect us to the sacred design behind our bodies. Paul Saladino dismantles processed-food orthodoxy, exposes the institutional incentives that keep us sick, and lays out a path back to strength, sovereignty, and clear thinking — from meat and mitochondria to seed oils, vaccines, addiction, metabolic disease, and the spiritual dimension of reclaiming health. Paul's book ("The Carnivore Code") — His foundational work on nutrient-dense eating, environmental toxins, and how animal-based nutrition can heal modern chronic illness: https://bit.ly/saladinobook Paul's website — Articles, research breakdowns, and his podcast "Fundamental Health," where he explores food, biology, psychology, and human thriving: https://www.paulsaladinomd.co Study mentioned in the ad — A new peer-reviewed paper cited by The Wellness Company reporting a potential association between mRNA vaccination and increased cancer risk, based on population-level biomarker analysis: https://biomarkerres.biomedcentral.com/articles/10.1186/s40364-025-00831-W

The Breggin Hour with Dr. Peter & Ginger Breggin – Karen's point that AI has been introduced just at a time when the human population is suffering from unprecedented amounts of neurological damage, from the mRNA vaccines as well as from other sources. She pointed out that the creators of the AI programs being used were doing the thinking—the cognitive work—for the individuals using it, which...

This Week in Review recaps ex-CDC Director Robert Redfield decrying mRNA vaccines as immunotoxic for healthy people while praising cancer applications, Stephen Miller's confident economic timeline from cheaper Thanksgiving to tax relief and nuclear revival, Florida SG Joseph Ladapo warning of enslavement forces at CHD conference, Elon Musk affirming Christ's teachings on forgiveness, and poll results demanding 68% for Trump to focus solely on domestic issues amid listener reactions.   AM Update Week in Review, Robert Redfield mRNA, Stephen Miller economy, Joseph Ladapo freedom, Elon Musk Christ, domestic focus poll, vaccine injury, affordability timeline, transhumanism warning, Trump priorities

Diagnostic radiologist Rakesh A. Shah discusses his article "A critique of medicine's response to RFK Jr." Rakesh argues that major physician organizations have failed in their duty to protect public health by remaining silent and timid in the face of Robert F. Kennedy Jr.'s anti-vaccine misinformation. He contends that this "cowardice" prioritizes institutional self-interest over patient welfare and endangers not just immunization programs but the future of medical research, including promising mRNA-based cancer treatments. This episode explores the crisis of leadership in organized medicine, the difference between being apolitical and surrendering to a public health threat, and why Rakesh believes this silence is a profound abdication of professional duty. Learn why he argues that when politicians show more courage than doctors, the very credibility of medicine is at stake. Our presenting sponsor is Microsoft Dragon Copilot. Want to streamline your clinical documentation and take advantage of customizations that put you in control? What about the ability to surface information right at the point of care or automate tasks with just a click? Now, you can. Microsoft Dragon Copilot, your AI assistant for clinical workflow, is transforming how clinicians work. Offering an extensible AI workspace and a single, integrated platform, Dragon Copilot can help you unlock new levels of efficiency. Plus, it's backed by a proven track record and decades of clinical expertise, and it's part of Microsoft Cloud for Healthcare, built on a foundation of trust. Ease your administrative burdens and stay focused on what matters most with Dragon Copilot, your AI assistant for clinical workflow. VISIT SPONSOR → https://aka.ms/kevinmd SUBSCRIBE TO THE PODCAST → https://www.kevinmd.com/podcast RECOMMENDED BY KEVINMD → https://www.kevinmd.com/recommended

In this explosive interview, Dr. Peter McCullough and epidemiologist Nicolas Hulscher expose the untold history, ideology, and corruption behind the global vaccine narrative — from Cotton Mather and Louis Pasteur to Fauci and the modern mRNA era. They reveal shocking evidence of contaminated polio shots, untested childhood vaccine schedules, and the CDC's deceptive reporting tactics that have silenced doctors who dare to question “the science.” Together, they uncover how fear, power, and profit created a modern-day religion of vaccinology that has replaced faith in God with faith in pharmaceuticals. Dr. McCullough also dives deep into the disturbing genetic chaos caused by mRNA shots — linking them to turbo cancers, blood clots, dementia, infertility, and transgenerational harm. They also discuss the alarming normalization of disease, the rise of autism and gender confusion, and the moral collapse of medicine that's putting children at risk. This is one of the most eye-opening conversations ever released on the Rebecca Weiss Podcast — a must-watch for anyone who values truth, freedom, and medical autonomy.

In this explosive interview, Dr. Peter McCullough and epidemiologist Nicolas Hulscher expose the untold history, ideology, and corruption behind the global vaccine narrative — from Cotton Mather and Louis Pasteur to Fauci and the modern mRNA era. They reveal shocking evidence of contaminated polio shots, untested childhood vaccine schedules, and the CDC's deceptive reporting tactics that have silenced doctors who dare to question “the science.” Together, they uncover how fear, power, and profit created a modern-day religion of vaccinology that has replaced faith in God with faith in pharmaceuticals. Dr. McCullough also dives deep into the disturbing genetic chaos caused by mRNA shots — linking them to turbo cancers, blood clots, dementia, infertility, and transgenerational harm. They also discuss the alarming normalization of disease, the rise of autism and gender confusion, and the moral collapse of medicine that's putting children at risk. This is one of the most eye-opening conversations ever released on the Rebecca Weiss Podcast — a must-watch for anyone who values truth, freedom, and medical autonomy.

[00:01:03] – Trump's Veterans Day with an Al-Qaeda LeaderKnight opens with outrage over Trump meeting a Syrian warlord linked to Al-Qaeda, framing it as proof of U.S. hypocrisy and the intelligence community's long alliance with terrorist networks. [00:06:56] – The 50-Year Mortgage and Debt SlaveryHe mocks Trump's plan for 50-year mortgages as the next stage of financial serfdom, arguing that Americans will “own nothing” while banks and the state profit from endless debt cycles. [00:42:06] – The CIA and the Birth of the Feral GovernmentKnight traces the origins of the national security state, accusing Truman's creation of the CIA and NSA of birthing an unaccountable “feral government” that now rules America through secrecy and surveillance. [01:09:19] – Feeding Candy to Cattle and mRNA MeatHe exposes candy companies selling waste candy as cattle feed and the USDA's quiet approval of mRNA livestock vaccines, calling it a convergence of food corruption and biotech experimentation. [01:11:22] – The FACE Act and Criminalized SpeechKnight examines how the FACE Act is being used to prosecute both pro-life and anti-war activists, warning it's a bipartisan tool for suppressing free expression under moral pretense. [01:34:13] – The Universities as Marxist SeminariesKnight argues modern academia has become an ideological indoctrination system rooted in the Frankfurt School — designed to dismantle faith, family, and free enterprise from within. [01:45:33] – The Clinton Foundation's Untouchable CrimesHe revisits Trump's refusal to pursue investigations into the Clinton Foundation, describing it as evidence of systemic bipartisan corruption shielding globalist elites. [02:03:06] – The Medical Coder Whistleblower: Zoe Smith's TestimonySmith exposes how hospitals received federal bonuses for COVID diagnoses and ventilator use, revealing how financial incentives turned healthcare into a profit-driven death machine. [02:23:37] – PCR Tests and Genetic Data HarvestingSmith explains that PCR testing was repurposed from diagnostic use into mass data collection, linking it to global DNA databases used for AI-driven biotech development. [02:59:40] – Cash Bans and the Digital Totalitarian FutureKnight closes warning that Europe's cash bans and central bank digital currencies represent the final step toward total economic surveillance and the end of financial freedom. Money should have intrinsic value AND transactional privacy: Go to https://davidknight.gold/ for great deals on physical gold/silverFor 10% off Gerald Celente's prescient Trends Journal, go to https://trendsjournal.com/ and enter the code KNIGHTFind out more about the show and where you can watch it at TheDavidKnightShow.com If you would like to support the show and our family please consider subscribing monthly here: SubscribeStar https://www.subscribestar.com/the-david-knight-showOr you can send a donation throughMail: David Knight POB 994 Kodak, TN 37764Zelle: @DavidKnightShow@protonmail.comCash App at: $davidknightshowBTC to: bc1qkuec29hkuye4xse9unh7nptvu3y9qmv24vanh7Become a supporter of this podcast: https://www.spreaker.com/podcast/the-david-knight-show--2653468/support.

[00:01:03] – Trump's Veterans Day with an Al-Qaeda LeaderKnight opens with outrage over Trump meeting a Syrian warlord linked to Al-Qaeda, framing it as proof of U.S. hypocrisy and the intelligence community's long alliance with terrorist networks. [00:06:56] – The 50-Year Mortgage and Debt SlaveryHe mocks Trump's plan for 50-year mortgages as the next stage of financial serfdom, arguing that Americans will “own nothing” while banks and the state profit from endless debt cycles. [00:42:06] – The CIA and the Birth of the Feral GovernmentKnight traces the origins of the national security state, accusing Truman's creation of the CIA and NSA of birthing an unaccountable “feral government” that now rules America through secrecy and surveillance. [01:09:19] – Feeding Candy to Cattle and mRNA MeatHe exposes candy companies selling waste candy as cattle feed and the USDA's quiet approval of mRNA livestock vaccines, calling it a convergence of food corruption and biotech experimentation. [01:11:22] – The FACE Act and Criminalized SpeechKnight examines how the FACE Act is being used to prosecute both pro-life and anti-war activists, warning it's a bipartisan tool for suppressing free expression under moral pretense. [01:34:13] – The Universities as Marxist SeminariesKnight argues modern academia has become an ideological indoctrination system rooted in the Frankfurt School — designed to dismantle faith, family, and free enterprise from within. [01:45:33] – The Clinton Foundation's Untouchable CrimesHe revisits Trump's refusal to pursue investigations into the Clinton Foundation, describing it as evidence of systemic bipartisan corruption shielding globalist elites. [02:03:06] – The Medical Coder Whistleblower: Zoe Smith's TestimonySmith exposes how hospitals received federal bonuses for COVID diagnoses and ventilator use, revealing how financial incentives turned healthcare into a profit-driven death machine. [02:23:37] – PCR Tests and Genetic Data HarvestingSmith explains that PCR testing was repurposed from diagnostic use into mass data collection, linking it to global DNA databases used for AI-driven biotech development. [02:59:40] – Cash Bans and the Digital Totalitarian FutureKnight closes warning that Europe's cash bans and central bank digital currencies represent the final step toward total economic surveillance and the end of financial freedom. Money should have intrinsic value AND transactional privacy: Go to https://davidknight.gold/ for great deals on physical gold/silverFor 10% off Gerald Celente's prescient Trends Journal, go to https://trendsjournal.com/ and enter the code KNIGHTFind out more about the show and where you can watch it at TheDavidKnightShow.com If you would like to support the show and our family please consider subscribing monthly here: SubscribeStar https://www.subscribestar.com/the-david-knight-showOr you can send a donation throughMail: David Knight POB 994 Kodak, TN 37764Zelle: @DavidKnightShow@protonmail.comCash App at: $davidknightshowBTC to: bc1qkuec29hkuye4xse9unh7nptvu3y9qmv24vanh7Become a supporter of this podcast: https://www.spreaker.com/podcast/the-real-david-knight-show--5282736/support.

Angel Studios https://Angel.com/HermanJoin the Angel Guild today and know you are not just watching, you're helping make bold, faith driven stories like Disciples in the Moonlight possible. That's Angel.com/HermanRenue Healthcare https://Renue.Healthcare/ToddYour journey to a better life starts at Renue Healthcare. Visit https://Renue.Healthcare/Todd Bulwark Capital https://KnowYourRiskPodcast.comRegister now for the free Review/Preview Webinar November 20th 3:30pm Pacific, schedule your free Know Your Risk Portfolio Review, and subscribe to Zach's Daily Market Recap at (SLOW) Know Your Risk Podcast dot com. Alan's Soaps https://www.AlansArtisanSoaps.comUse coupon code TODD to save an additional 10% off the bundle price.Bonefrog https://BonefrogCoffee.com/toddThe new GOLDEN AGE is here!  Use code TODD at checkout to receive 10% off your first purchase and 15% on subscriptions.Ben Shapiro has become a hall monitor, per se. There are certain things you can't talk about. You cannot question the government of Israel around Ben Shapiro, and up until very recently, you couldn't ask questions about the mRNA injections.Episode Links:Mark Levin reads private text messages with Tucker Carlson revealing that TPUSA wanted the two men to debate. Carlson said he was open to debate but Levin refused because he didn't want to “platform” Carlson. Levin then bragged about his “rational” response where he called Carlson “the modern-day David Duke.” What a bizarre response.“I don't want to have a war with Ben Shapiro...” @TuckerCarlson on whether he and Ben Shapiro can find a way to detente.Qatar sent millions to Gaza for years – with Israel's backing. Here's what we know about the controversial dealFormer Capitol Police officer a forensic match for Jan. 6 pipe bomber, sources sayBen Shapiro admitting we were lied to by everyone including Pfizer, the government & the scientists compiled with new clips of him shaming people for asking question

Aaron McIntire breaks down President Trump's push to reopen the federal government amid a Democrat's candid revelation on party entrenchment in Obamacare subsidies. Plus, Trump's bold vision for direct-to-citizen healthcare payments and $2,000 tariff dividends to tackle national debt; Supreme Court sidesteps "same-sex marriage" challenge but takes on post-Election Day ballots; Olympics eye blanket transgender athlete ban; updates on Ilhan Omar's deportation defiance, Elon Musk's AI prison rethink, GOP cooling on marijuana, the deepening Cybertruck bombing mystery, ex-CDC chief's mRNA vaccine regrets, and a big-picture warning on transhumanism's power grab.   government shutdown, Trump healthcare, tariff dividends, Supreme Court cases, same-sex marriage, election ballots, Olympics transgender ban, Ilhan Omar, Elon Musk AI, marijuana legalization, Cybertruck bombing, mRNA vaccines, Robert Redfield, transhumanism

Over the last five years, billions of people have received at least one dose of a COVID-19 mRNA vaccine. New research has found an unanticipated result of these vaccines: Cancer treatments are more effective for some vaccinated patients, and many live longer than their unvaccinated counterparts. This news comes at a time where the federal government is slashing funding for mRNA research. Host Ira Flatow speaks to lead study author Adam Grippin and vaccine expert Eric Topol.Guests: Dr. Adam Grippin is a radiation oncologist at the MC Anderson Cancer Center in Houston, Texas. Dr. Eric Topol is a cardiologist and genomics professor at the Scripps Research Institute in La Jolla, California.Transcripts for each episode are available within 1-3 days at sciencefriday.com. Subscribe to this podcast. Plus, to stay updated on all things science, sign up for Science Friday's newsletters.

Numerous COVID-19 Vaccine Studies Point to Overwhelming Risks. Dr. McCullough, Dr. Nicolas Hulscher and 8 X Shorts. Nicolas Hulscher  BREAKING: Two Studies Confirm COVID-19 "Vaccines" Act as Chemical Lobotomies — 146 Serious Brain, Spinal Cord, and Psychiatric Adverse Events Identified CDC/FDA safety signals BREACHED for prion disease, encephalitis, brain abscesses, dementia, schizophrenia, suicidal and homicidal thoughts, stroke, psychosis, depression, cognitive impairment, delusions, meningitis, myelitis, demyelination syndromes, and MANY more. The shots disrupt the blood–brain barrier, allowing mRNA, amyloidogenic spike proteins and pathogens to penetrate the brain and spinal cord — an outcome consistent with the skyrocketing rates of cognitive decline now seen across the world. 8 X Shorts on Vaccination Risks. --------------------------------------------------------------------  Check out our ACU Patreon page: https://www.patreon.com/ACUPodcast   HELP ACU SPREAD THE WORD!  Please go to Apple Podcasts and give ACU a 5 star rating. Apple canceled us and now we are clawing our way back to the top. Don't let the Leftist win. Do it now! Thanks. Also Rate us on any platform you follow us on. It helps a lot. Forward this show to friends. Ways to subscribe to the American Conservative University Podcast Click here to subscribe via Apple Podcasts Click here to subscribe via RSS You can also subscribe via Stitcher FM Player Podcast Addict Tune-in Podcasts Pandora Look us up on Amazon Prime …And Many Other Podcast Aggregators and sites ACU on Twitter- https://twitter.com/AmerConU . Warning- Explicit and Violent video content.   Please help ACU by submitting your Show ideas. Email us at americanconservativeuniversity@americanconservativeuniversity.com   Endorsed Charities -------------------------------------------------------- Pre-Born! Saving babies and Souls. https://preborn.org/ OUR MISSION To glorify Jesus Christ by leading and equipping pregnancy clinics to save more babies and souls. WHAT WE DO Pre-Born! partners with life-affirming pregnancy clinics all across the nation. We are designed to strategically impact the abortion industry through the following initiatives:… -------------------------------------------------------- Help CSI Stamp Out Slavery In Sudan Join us in our effort to free over 350 slaves. Listeners to the Eric Metaxas Show will remember our annual effort to free Christians who have been enslaved for simply acknowledging Jesus Christ as their Savior. As we celebrate the birth of Christ this Christmas, join us in giving new life to brothers and sisters in Sudan who have enslaved as a result of their faith. https://csi-usa.org/metaxas   https://csi-usa.org/slavery/   Typical Aid for the Enslaved A ration of sorghum, a local nutrient-rich staple food A dairy goat A “Sack of Hope,” a survival kit containing essential items such as tarp for shelter, a cooking pan, a water canister, a mosquito net, a blanket, a handheld sickle, and fishing hooks. Release celebrations include prayer and gathering for a meal, and medical care for those in need. The CSI team provides comfort, encouragement, and a shoulder to lean on while they tell their stories and begin their new lives. Thank you for your compassion  Giving the Gift of Freedom and Hope to the Enslaved South Sudanese -------------------------------------------------------- Food For the Poor https://foodforthepoor.org/ Help us serve the poorest of the poor Food For The Poor began in 1982 in Jamaica. Today, our interdenominational Christian ministry serves the poor in primarily 17 countries throughout the Caribbean and Latin America. Thanks to our faithful donors, we are able to provide food, housing, healthcare, education, fresh water, emergency relief, micro-enterprise solutions and much more. We are proud to have fed millions of people and provided more than 15.7 billion dollars in aid. Our faith inspires us to be an organization built on compassion, and motivated by love. Our mission is to bring relief to the poorest of the poor in the countries where we serve. We strive to reflect God's unconditional love. It's a sacrificial love that embraces all people regardless of race or religion. We believe that we can show His love by serving the “least of these” on this earth as Christ challenged us to do in Matthew 25. We pray that by God's grace, and with your support, we can continue to bring relief to the suffering and hope to the hopeless.   Report on Food For the Poor by Charity Navigator https://www.charitynavigator.org/ein/592174510   -------------------------------------------------------- Disclaimer from ACU. We try to bring to our students and alumni the World's best Conservative thinkers. All views expressed belong solely to the author and not necessarily to ACU. In all issues and relations, we hope to follow the admonitions of Jesus Christ. While striving to expose, warn and contend with evil, we extend the love of God to all of his children. ----------------------------------------------------------------------------------------- 

RFK Jr. says that new dietary guidelines will be released in December and he claims they will change food culture in the U.S. We can hope this change is positive, but considering how RFK Jr has backed mRNA, rubber stamped a MAHA report with AI writing and errors, and push processed prepared meals, the change might be negative. Already the USDA recommends vegetables and fruits, but RFK Jr. has hinted how the new guidelines will include more promotion of meat and dairy products, though he say “Whole Foods” will be a big part of the new guidance. Is it possible the guidelines get worse? Does it matter when few consult them to begin with? What does it matter when some States try to independently start initiatives that lack funding and respect anyway? Even if the entire government of every state moved in a positive direction is it possible the public would rebel? At the core of this problem is a cultural issue that neglects food education, or what the Japanese call Shokuiku, and it extends to healthcare in general. *The is the FREE archive, which includes advertisements. If you want an ad-free experience, you can subscribe below underneath the show description.FREE ARCHIVE (w. ads)SUBSCRIPTION ARCHIVEX / TWITTER FACEBOOKWEBSITEBuyMe-CoffeePaypal: rdgable1991@gmail.comCashApp: $rdgable EMAIL: rdgable@yahoo.com /TSTRadio@protonmail.comBecome a supporter of this podcast: https://www.spreaker.com/podcast/the-secret-teachings--5328407/support.

In his weekly clinical update, Dr. Griffin with Vincent Racaniello discusses the link between in utero SARS-CoV-2 infection and poor neurodevelopment outcomes, the use of an mRNA vaccine as an anti-cancer therapy, why one should receive the HPV vaccine, asymptomatic H5N1 isolations in humans, and H5N1 on turkey farms, before Dr. Griffin deep dives into recent statistics on the measles epidemic, RSV, influenza and SARS-CoV-2 infections, the Wasterwater Scan dashboard, Johns Hopkins measles tracker, how two vaccinated physicians became infected with measles, effective of COVID-19 vaccine for children, where to find PEMGARDA, how to access and pay for Paxlovid, can you be retreated with Paxlovid, long COVID treatment center, where to go for answers to your long COVID questions, how a specific antibody type may associate with recovery from long COVID, if use of a probiotic is helpful to treat mild COVID-19, if vaccination helps prevent long in adolescents and contacting your federal government representative to stop the assault on science and biomedical research. Subscribe (free): Apple Podcasts, RSS, email Become a patron of TWiV! Links for this episode Neurodevelopmental Outcomes of 3-Year-Old Children Exposed to Maternal Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in Utero (Obstetrics & Gynecology) SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade (Nature) TWiV 1267: A cancer vaccine and an mpox treatment (microbeTV: TWiV1267) Cancers Caused by HPV (CDC: Human papillomavirus (HPV)) Circulating tumor human papillomavirus DNA whole genome sequencing enables human papillomavirus-associated oropharynx cancer early detection (Journal of National Cancer Institute) Impact of Vaccinating Adult Women Who Are HPV-Positive or with Confirmed Cervical SIL with the 9-Valent Vaccine (Viruses) ACIP Shared Clinical Decision-Making Recommendations (CDC: Advisory Committee on Immunization Practices (ACIP)) HPV Vaccination Recommendation (CDC: Vaccines & Immunizations) Asymptomatic Human Infections With Avian Influenza A(H5N1) Virus Confirmed by Molecular and Serologic Testing (JAMA: OPEN Network) Review: Human H5N1 avian flu cases can be asymptomatic, and the virus likely spreads among people (CIDRAP) Avian flu strikes turkey farms in Dakotas, large egg facility in California (CIDRAP) Another Doctor at Ichilov Contracts Measles After Treating Unvaccinated Child (gov.il) Wastewater for measles (WasterWater Scan) Measles cases and outbreaks (CDC Rubeola) Tracking Measles Cases in the U.S. (Johns Hopkins) Measles vaccine recommendations from NYP (jpg) Weekly measles and rubella monitoring (Government of Canada) Measles (WHO) Get the FACTS about measles (NY State Department of Health) Measles (CDC Measles (Rubeola)) Measles vaccine (CDC Measles (Rubeola)) Presumptive evidence of measles immunity (CDC) Contraindications and precautions to measles vaccination (CDC) Measles (CDC Measles (Rubeola)) Adverse events associated with childhood vaccines: evidence bearing on causality (NLM) Measles Vaccination: Know the Facts (ISDA: Infectious Diseases Society of America) Deaths following vaccination: what does the evidence show (Vaccine) Influenza: Waste water scan for 11 pathogens (WastewaterSCan) US respiratory virus activity (CDC Respiratory Illnesses) Respiratory virus activity levels (CDC Respiratory Illnesses) Weekly surveillance report: clift notes (CDC FluView) ACIP Recommendations Summary (CDC: Influenza) Influenza Vaccine Composition for the 2025-2026 U.S. Influenza Season (FDA) RSV: Waste water scan for 11 pathogens (WastewaterSCan) Respiratory Diseases (Yale School of Public Health) US respiratory virus activity (CDC Respiratory Illnesses) RSV-Network (CDC Respiratory Syncytial virus Infection) Vaccines for Adults (CDC: Respiratory Syncytial Virus Infection (RSV)) Economic Analysis of Protein Subunit and mRNA RSV Vaccination in Adults aged 50-59 Years (CDC: ACIP) Waste water scan for 11 pathogens (WastewaterSCan) COVID-19 deaths (CDC) Respiratory Illnesses Data Channel (CDC: Respiratory Illnesses) COVID-19 national and regional trends (CDC) COVID-19 variant tracker (CDC) SARS-CoV-2 genomes galore (Nextstrain) Antigenic and Virological Characteristics of SARS-CoV-2 Variant BA.3.2, XFG, and NB.1.8.1 (bioRxiV) Vascular and inflammatory diseases after COVID-19 infection and vaccination in children and young people in England (LANCET: Child & Adolescent Health) Where to get pemgarda (Pemgarda) EUA for the pre-exposure prophylaxis of COVID-19 (INVIYD) Infusion center (Prime Fusions) CDC Quarantine guidelines (CDC) NIH COVID-19 treatment guidelines (NIH) Drug interaction checker (University of Liverpool) Help your eligible patients access PAXLOVID with the PAXCESS Patient Support Program (Pfizer Pro) Understanding Coverage Options (PAXCESS) Real-World Effectiveness of Nirmatrelvir-Ritonavir in Preventing Coronavirus Disease 2019–Associated Hospitalization (CID) Infectious Disease Society guidelines for treatment and management (ID Society) Molnupiravir safety and efficacy (JMV) Convalescent plasma recommendation for immunocompromised (ID Society) What to do when sick with a respiratory virus (CDC) Managing healthcare staffing shortages (CDC) Anticoagulation guidelines (hematology.org) Daniel Griffin's evidence based medical practices for long COVID (OFID) Long COVID hotline (Columbia : Columbia University Irving Medical Center) The answers: Long COVID SARS-CoV-2 spike-specific IgG4 class switching associates with clinical recovery in Long COVID (Journal of Infection) Efficacy of Lactococcus lactis Strain Plasma in Patients with Mild COVID-19 (Infectious Diseases and Therapy) Preventive effect of vaccination on long COVID in adolescents with SARS-CoV-2 infection (Vaccine) Reaching out to US house representative Letters read on TWiV 1268 Dr. Griffin's COVID treatment summary (pdf) Timestamps by Jolene Ramsey. Thanks! Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to daniel@microbe.tv Content in this podcast should not be construed as medical advice.

Filmed live before a studio audience, Del Bigtree and Jefferey Jaxen break down Bill Gates' shocking reversal on climate change — signaling that the global narrative may finally be unraveling. Then, a new American Heart Association study reveals alarming data on the COVID vaccine's impact on the heart — a discovery that could mark the final blow for mRNA technology. Plus, an unprecedented in-studio panel brings together Dr. Andrew Wakefield, Dr. Pierre Kory, and Dr. Suzanne Humphries — three medical truth-tellers confronting the biggest questions of our time: Are we witnessing the collapse of a system built on misinformation? Or the rebirth of true science and transparency?Watch this powerful new episode of The HighWire, where the truth always comes straight from the heart.Guests: Dr. Suzanne Humphries, Dr. Pierre Kory, Dr. Andrew WakefieldBecome a supporter of this podcast: https://www.spreaker.com/podcast/the-highwire-with-del-bigtree--3620606/support.

On Election Day 2025, buckle up for a no-holds-barred episode. We're showing the White House's "My Safe Space" Facebook page— tribute to the Democrats—while unpacking bomb threats crippling New Jersey polling sites and voting machine glitches suspiciously targeting red districts. And in Virginia, Barack Obama's hypocritical endorsement of DEI-pushing Abigail Spanberger over trailblazing Black Republican Winsome Earle-Sears? We'll break down the left's "systemic racism" flip-flop with fiery audio that makes you question: politics or principles?Shifting gears to the Big Apple, Elon's torching NYC's mayoral ballot as a straight-up scam—no ID, duplicate names, Cuomo buried at the bottom. Then, meet Zohran Mamdani, the socialist firebrand whose "Democrat" word salad has street-level libs drooling over government-run grocery stores and "lifting everybody up" with zero clue on costs. We'll roll clips of clueless voters, a ranting communist vowing to seize food industries, and a white liberal's wildest worries: ICE raids on illegals and kids' sex changes. It's peak progressive absurdity, straight from the rallies—proving Europe's Muslim power grabs and Dearborn's call-to-prayer wake-ups are just a Mamdani win away.But it's not all outrage—join us for a raw, eye-opening chat with Vaccine Choice Canada's Ted Kuntz, whose son's DPT nightmare sparked a 40-year crusade for medical freedom. From underreported seizures to mRNA red flags, he'll torch the industry's "safety" lies and champion informed consent over herd immunity hype. We also have a blistering fax blast demanding Congress deport 'em all or face removal, slamming sanctuary treason from Pritzker to Omar. Tune in—because if we don't fight the invasion now, America's ballot box becomes its battlefield. Don't miss the untamed truth!

[00:02:55] – Trump's Tariff Dictatorship & Fake EmergenciesKnight calls Trump's “emergency tariffs” case the blueprint for economic dictatorship, saying Congress has handed the president Caesar-style powers to rule by declaration. [00:11:12] – The Punisher Police StateKnight exposes how law enforcement's obsession with the Punisher logo mirrors America's descent into militarized authoritarianism — a culture where violence replaces justice. [00:31:56] – Trump's Assault on the Rule of LawKnight argues Trump turned the Constitution into political theater, using “emergency powers” and a cult of personality to replace lawful governance with ego-driven tyranny. [00:53:39] – Elon Musk, H-1B, and the Technocratic TrapKnight tears into Musk's Rogan appearance, saying Musk's visa policies and AI automation push “top-down population replacement.” He brands Musk and Silicon Valley as “authoritarian overlords disguised as innovators.” [01:09:10] – The Masters of the Universe SpeechKnight plays footage from the Republican Jewish Coalition where a speaker boasts, “The masters of the universe are Jews.” [01:33:42] – Epstein Files, Mike Johnson & The Cover-UpKnight blasts Speaker Mike Johnson for blocking Epstein file releases, praising Marjorie Taylor Greene's promise to read names aloud in Congress. “The pedophile class,” he says, “owns both parties.” [01:45:09] – The Anti-Speech Laws & Real ID StateKnight condemns GOP-backed laws banning Israel criticism and mandating digital ID compliance, calling it the merger of Zionism and technocracy — censorship under the flag of patriotism. [02:19:20] – “mRNA Is Pure Poison”Dr. Brian Hooker says mRNA vaccines are a depopulation tool masked as medicine. He cites over a million U.S. deaths and calls for an outright ban on “Fauci's bioweapon empire.” [02:35:41] – Contamination & SV40 Cancer RiskHooker reveals vaccine contamination with E. coli and SV40 viral DNA — a known carcinogen. He calls it “DARPA's biotech soup,” proof that mRNA production was a reckless military experiment, not medicine. Follow the show on Kick and watch live every weekday 9:00am EST – 12:00pm EST https://kick.com/davidknightshow Money should have intrinsic value AND transactional privacy: Go to https://davidknight.gold/ for great deals on physical gold/silverFor 10% off Gerald Celente's prescient Trends Journal, go to https://trendsjournal.com/ and enter the code KNIGHTFind out more about the show and where you can watch it at TheDavidKnightShow.com If you would like to support the show and our family please consider subscribing monthly here: SubscribeStar https://www.subscribestar.com/the-david-knight-showOr you can send a donation throughMail: David Knight POB 994 Kodak, TN 37764Zelle: @DavidKnightShow@protonmail.comCash App at: $davidknightshowBTC to: bc1qkuec29hkuye4xse9unh7nptvu3y9qmv24vanh7Become a supporter of this podcast: https://www.spreaker.com/podcast/the-david-knight-show--2653468/support.

Freedom Angels founders Denise Aguilar and Tara Thorton describe how they (a former gang member and a former liberal) came together under the common mission to protect children in California against state leadership hell-bent on doing irreparable damage to them.  In this episode the Freedom Angels warn the rest of the nation about Governor Gavin Newsom who wants to be President more than anything on the planet and will stop at nothing in that pursuit. Newsom used isolation and fear tactics to force the mRNA vaccine on the public, created a sanctuary state to sterilize and mutilate children, strip parental rights, and put Californians in peril for his own political aspirations. Now, Newsom's massive gerrymandering scheme aims to steal 5 congressional seats in California with next week's special election. The Freedom Angels have a plan to fight back against California's disastrous leadership starting at the local level.